BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 29127680)

  • 1. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
    Dong AC; Rivella S
    Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Era for Hemoglobinopathies: More Than One Curative Option.
    Psatha N; Papayanni PG; Yannaki E
    Curr Gene Ther; 2017; 17(5):364-378. PubMed ID: 29357790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Therapy for β-Hemoglobinopathies.
    Cavazzana M; Antoniani C; Miccio A
    Mol Ther; 2017 May; 25(5):1142-1154. PubMed ID: 28377044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
    Sii-Felice K; Giorgi M; Leboulch P; Payen E
    Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
    Magrin E; Miccio A; Cavazzana M
    Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
    Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
    PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.
    Negre O; Eggimann AV; Beuzard Y; Ribeil JA; Bourget P; Borwornpinyo S; Hongeng S; Hacein-Bey S; Cavazzana M; Leboulch P; Payen E
    Hum Gene Ther; 2016 Feb; 27(2):148-65. PubMed ID: 26886832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic therapy for beta-thalassemia: from the bench to the bedside.
    Arumugam P; Malik P
    Hematology Am Soc Hematol Educ Program; 2010; 2010():445-50. PubMed ID: 21239833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Therapy for beta-thalassemia.
    Malik P; Arumugam PI
    Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials.
    Segura EER; Ayoub PG; Hart KL; Kohn DB
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemoglobin gene therapy for β-thalassemia.
    Bank A
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1187-201. PubMed ID: 21075288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
    Persons DA
    Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia.
    Sadelain M
    Curr Opin Hematol; 2006 May; 13(3):142-8. PubMed ID: 16567956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies.
    Payen E; Leboulch P
    Hematology Am Soc Hematol Educ Program; 2012; 2012():276-83. PubMed ID: 23233592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study.
    Urbinati F; Campo Fernandez B; Masiuk KE; Poletti V; Hollis RP; Koziol C; Kaufman ML; Brown D; Mavilio F; Kohn DB
    Hum Gene Ther; 2018 Oct; 29(10):1153-1166. PubMed ID: 30198339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lentiviral vector ALS20 yields high hemoglobin levels with low genomic integrations for treatment of beta-globinopathies.
    Breda L; Ghiaccio V; Tanaka N; Jarocha D; Ikawa Y; Abdulmalik O; Dong A; Casu C; Raabe TD; Shan X; Danet-Desnoyers GA; Doto AM; Everett J; Bushman FD; Radaelli E; Assenmacher CA; Tarrant JC; Hoepp N; Kurita R; Nakamura Y; Guzikowski V; Smith-Whitley K; Kwiatkowski JL; Rivella S
    Mol Ther; 2021 Apr; 29(4):1625-1638. PubMed ID: 33515514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Therapy Approaches to Hemoglobinopathies.
    Ferrari G; Cavazzana M; Mavilio F
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):835-852. PubMed ID: 28895851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome Editing for the β-Hemoglobinopathies.
    Porteus MH
    Adv Exp Med Biol; 2017; 1013():203-217. PubMed ID: 29127682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number.
    Persons DA; Hargrove PW; Allay ER; Hanawa H; Nienhuis AW
    Blood; 2003 Mar; 101(6):2175-83. PubMed ID: 12411297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Therapy and Genome Editing.
    Boulad F; Mansilla-Soto J; Cabriolu A; Rivière I; Sadelain M
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):329-342. PubMed ID: 29458735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.